

Apposite Capital Makes New Investment in Award-Winning Medical Device Company Emblation

London and Alloa, UK – 24th May 2021. Apposite Capital, the healthcare investor, today announces that it has invested in fast-growing medical device company, Emblation, to support its international growth and broaden its go-to market offering.

Created in 2007 by Gary Beale and Eamon McErlean, Emblation designs, manufactures and commercialises next generation microwave-based solutions for a range of skin conditions. The award-winning and clinically proven technology, SWIFT[®], offers a non-ablative, highly effective treatment for common and plantar warts. Emblation's products are also used in the treatment of certain cancers. Emblation's systems are currently sold in the UK, North America and Australia, and have been used in over 130,000 treatments to date.

Alongside the investment, Jim Atkinson, former VP Sales of Ulthera Inc, a prior Apposite Capital portfolio company focused on aesthetic medical devices, has been appointed to the Emblation Board together with Rory Pope, Partner, Apposite Capital.

Commenting on this final platform investment from Apposite Healthcare Fund II, Rory Pope said: "We are delighted to support a business that is delivering an enhanced patient experience and superior results in the fields of podiatry and dermatology. SWIFT[®]'s low energy microwave technology is unique and Emblation is well-positioned to continue delivering clinical breakthroughs and growth in adjacent pre-cancerous and cancerous indications. We are looking forward to working with Gary and the team as Emblation enters the next phase of its growth."

Gary Beale, CEO added: "We are pleased to have secured an investment from Apposite Capital which will allow us to accelerate our international expansion into new and existing markets as well as continue to build on our technology platform and deliver ground-breaking clinical results. Apposite immediately recognised the growth potential of our technology, and I am particularly excited to be working with the firm given their understanding of the sector and their expertise in scaling-up businesses like ours."

Advisers to Apposite Capital: Stephenson Harwood (legal), KPMG (accounting and tax)
Advisers to Emblation: William Blair (corporate finance), MacDonald Henderson (legal), Mazars (accounting and tax)

-end -

Media contacts:

Apposite Capital: Valerie Auffray, Tel : +44(0)203 475 1710, valerie.auffray@appositecapital.com
Emblation: Jonathan Williamson, Tel: +44 (0)1259 236 132, Jonathan.williamson@emblation.com

About Emblation

Emblation is an award-winning medical technology company, revolutionising the way microwave energy is used in healthcare. Its aim is to improve on traditional treatments, using the unique advantages microwaves deliver – accurate, repeatable procedures, and better clinical outcomes.

Emblation's technology is transforming the treatment of HPV infections globally, and is widely used in Dermatology, Podiatry and Oncology, with a number of disruptive applications under development in the fields of Cardiology and Gynaecology.

The company was started in 2007 by joint co-founders Gary Beale and Eamon McErlean (current Chief Executive Officer and Chief Technology Officer), the inventors behind the technology. They form part of the management team, with over 50 years of experience in this field.

Emblation's medical devices can be found in 1000s of clinics and hospitals across the UK, North America, and Australia, and the company is headquartered in central Scotland, UK.

About SWIFT technology

SWIFT® is the pioneering microwave therapy treatment for skin. With treatment times in seconds, SWIFT® provides Podiatrists and Dermatologists with a new, precise, and easy procedure for soft tissue lesions.

The SWIFT® treatment works by delivering a highly controlled dose of energy into the tissue, which creates heat and stimulates an immune response. This reduces the risks associated with destructive modalities, and results in highly effective outcomes for stubborn skin lesions.

About Apposite Capital (www.appositecapital.com)

Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life sciences and digital health.

Apposite Capital operates at the small end of the private equity market, providing both capital and expertise to those businesses offering 'disruptive' models that aim to improve or reduce the cost of care provision and which have the potential to become market leaders.

Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies.

Apposite Capital was established in 2006 and is headquartered in London, UK.